
It had a similar effect in 72 percent of salvage therapy patients, who take a mixture of existing medications aimed at stalling the virus until new drugs appear. The drug essentially prevents the virus' DNA from integrating with a host's cells, inhibiting its ability to replicate itself.
The U.S. Food and Drug Administration should approve it in mid-2007. Manufacturer Merck & Co. is making it available sooner to patients in desperate straits.
Comments